Business Wire

RIX Industries and Element 1 Corporation Partner to Deploy Hydrogen Generators for Fuel Cell Propulsion Systems

8.10.2020 19:39:00 EEST | Business Wire | Press release

Share

RIX Industries (“RIX”), a leading developer of pneumatic energy technology, announced today that it has licensed proprietary methanol-based M-Series hydrogen generator technology from Element 1 Corp (e1). Under the terms of the license agreement, RIX has been granted rights to manufacture and deploy e1’s M-Series on-board hydrogen generators for use in fuel cell mobility applications, including marine vessels and off-road vehicles such as mining trucks, tractors, and heavy-lift trucks in both North America and Europe.

Governments across the globe are striving to reduce harmful emissions into the air and waterways. Tightening regulations combined with corporate sustainability initiatives are driving a massive migration to non-polluting electric propulsion systems, many of which utilize hydrogen fuel cells. RIX’s history of supporting the maritime industry, including the US Navy, together with e1’s methanol to hydrogen generator offers end-users an opportunity to adopt fuel cell motive solutions and work towards a zero-emissions future.

“RIX Industries has a global reputation for excellence and the addition of e1’s class-leading technology to our portfolio strategically aligns with our brand and our growth strategy,” said Bryan Reid, Chief Sales Officer at RIX. “We are focused on the clean energy future and firmly believe that there is a significant market opportunity that can be effectively addressed by RIX incorporating e1’s M-Series hydrogen generator into power solutions.”

Dr. David Edlund, e1 CEO, said, “e1 is delighted and privileged to be collaborating with RIX. They are a first-class manufacturing partner and a long-time authorized supplier to multiple branches of the U.S. military along with a wide range of commercial and industrial end-users. The on-board hydrogen generation technology being licensed to RIX is unique to e1 and is highly enabling to the mass commercialization of fuel cell systems for a wide variety of transportation-related fuel cell applications. I anticipate our relationship with RIX to broaden substantially over the not too distant future,” concluded Dr. Edlund.

The onboard storage of methanol used by e1’s hydrogen generators requires a fraction of the space on a maritime vessel as compared to compressed hydrogen, enabling a significantly greater range between fueling. This range extension is critical for not only marine vessels but also for heavy and medium-duty fuel cell trucks traveling long distances each day.

About RIX Industries:

Founded in 1878, RIX Industries is a technology-focused company, headquartered in Benicia, CA, specializing in the design, development and manufacture of pneumatic energy storage, transfer and control system solutions, including gas generation systems, precision compressor solutions and cryogenic cooling technologies for critical applications in Marine, Aerospace, Land, Energy, Industrial and Medical markets.

Visit www.CreateCompressCool.com for more information.

About Element 1 Corporation:

Element 1 designs and develops novel processes to enable the commercialization of clean-energy products and processes and alternative-energy technology. Through licensing our IP to strategic partners, our mission is to significantly reduce barriers to the adoption of hydrogen technology and fuel cells for a range of applications and to reduce the waste and pollution associated with flaring natural gas.

For more information about Element 1, please visit www.e1na.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Elizabeth Schroeder
Marketing Manager
RIX Industries
Phone: 707.745.7198
E-mail: eschroeder@rixindustries.com

Robert Schluter
President
Element 1 Corporation
Phone: 541.678.5943
E-mail: robert@e1na.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye